TRexBio Prices IPO at $14 Per Share
TRexBio priced its initial public offering of 8,333,334 common shares at $14.00 per share. The offering is expected to raise approximately $116.7 million in gross proceeds before underwriting discounts and other expenses. Trading is expected to start on the Nasdaq Global Select Market on October 9, 2026, with closing expected on October 13, 2026, and underwriters have a 30-day option for up to 1,250,000 additional shares.
TRexBio, a South San Francisco clinical-stage biotechnology company with the planned Nasdaq ticker TRXB, focuses on tissue Treg biology to discover and develop immunoregulatory medicines. Its IPO consists entirely of newly offered shares from the company, not selling stockholders.
The company set the IPO price at $14.00 for 8,333,334 shares, implying about $116.7 million in gross proceeds before fees. Nasdaq Global Select Market trading is expected to begin October 9, 2026, with the deal closing October 13, 2026. Underwriters may buy up to 1,250,000 more shares within 30 days.
The offering may affect investors and existing shareholders through ownership dilution, while giving TRexBio capital that could support early-stage research. Patients with immune-related conditions might eventually benefit if the company’s tissue Treg programs advance, though clinical success remains uncertain. Broader market observers may view the listing as a signal about appetite for clinical-stage biotech offerings. Employees and researchers could also be affected if added funding changes hiring or research priorities. These outcomes are possibilities, not guarantees.